Velinor

Velinor Pharma is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of innovative topical treatments for inflammatory skin diseases. The company was founded in 2021 by a team of seasoned industry executives from LEO Pharma and Novo Nordisk, aiming to address the high unmet need in dermatology. Its lead candidate, VP-001, is a first-in-class small molecule currently undergoing Phase 2 clinical trials for the treatment of plaque psoriasis. Velinor's approach focuses on localized delivery to maximize therapeutic effect while minimizing systemic side effects. The company is backed by prominent European investors, including Sunstone Life Science Ventures and Lundbeckfonden BioCapital. Through its specialized expertise, Velinor seeks to redefine the standard of care for patients suffering from chronic skin conditions.